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Introduction Table 1 Patient details 
Patients may find fibreoptic bronchoscopy 
unpleasant (1,2). 
Doses of intravenous midazolam suggested for 
intravenous sedation (around 0.07 mg kg-‘) may not 
produce complete amnesia (3,4). We looked at safety, 
patient acceptability and some practical aspects of 
running a day case bronchoscopy service using a 
higher dose equivalent to that recommended for 
induction of anaesthesia. As we have used this 
‘asleep’ technique for several years we did not think it 
reasonable to have an ‘awake’ control group but 
hoped to compare our results with other published 
studies. 
Male/female 
Age (years) 
FEV, (% predicted) 
FVC (% predicted) 
FEV,IFVC ratio 
x3/45 
62.9 + 14.7 
71.9 & 22.9 
87.3 + 21.9 
65.2 f 13.8 
Mean f SD. 
resuscitation equipment was available. An anaesthe- 
tist was not present but nearby in an adjacent unit. 
Note was made of when after the procedure the 
patient had fully woken up and also an estimate 
made by the nursing staff as to when the patient was 
fit to go home. 
Patients and Methods 
Patient details are given in Table 1. Patients were 
pre-medicated with atropine, given 5 ml of 1% 
lignocaine gel into each nostril and supplemental 
oxygen at 3 1 min- ’ by nasal prongs directed into the 
mouth. 
Patients were seen in the outpatients within 3 days. 
They were then asked to take home with them a 
questionnaire which asked 
1. Did you find the bronchoscopy: intolerable; 
very unpleasant; mildly unpleasant; not unpleasant. 
2. Would you be prepared to have another bron- 
choscopy done: yes; no. 
Patients were then given small boluses of intrave- 
nous midazolam slowly over several minutes until 
they were judged to be lightly asleep. Four millilitres 
of 2% lignocaine was sprayed through the broncho- 
scope over the vocal cords and further aliquots of 
2 ml into the bronchial tree as required to control 
coughing, which was troublesome for the bronchos- 
copist. 
3. Do you remember anything about the test being 
done? 
Patients were monitored with a continuous ECG 
display (Roche 103 monitor Digital Electronics 
Limited) and pulse oximeter (Nellcor Pulse Oximeter 
model NlOOE) employing a finger probe. The oxi- 
meter alarms were set to go off if the saturation fell 
below 90% and the pulse below 50 or above 120. Full 
They were asked to post it back to a local general 
practitioner unknown to them. It was explained to 
them that their replies could not be identified. 
As only 50 of the first 73 questionnaires were 
returned, the next 50 consecutive patients were given 
questionnaires to be completed before leaving the 
hospital. 
Results 
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The dose of midazolam used varied between 5 and 
42.5 mg (0.07-0.67 mg kg-’ bodyweight mean 
0.24 f 0.1 one standard deviation). 
Details of oxygen saturation, blood pressure and 
pulse changes are shown in Table 2. Comparing 
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Table 2 Blood pressure, pulse and oxygen saturation details during bronchoscopy 
Systolic B.P. Diastolic B.P. 
(A) Before supplemental oxygen 144.7 f 27.6 85.6 f 13.1 
(B) With oxygen 143.1 f 25.2 85.6 f 12.4 
(C) After i.v. midazolam 129.9 f 21.7 79.3 f 12.8 
(D) After passing through larynx 151.0 + 29.2 93.5 + 21.7 
(E) After extubation 139.3 f 27.5 85.1 f 14.9 
Pulse 0, saturation 
87.2 f 15.3 95.7 f 2.2 
86.9 f 17.1 97.9 f 1.8 
93.9 f 14.2 96.7 f 2.9 
99.6 zk 16.1 94.9 f 3.3 
98.0 f 14.6 95.0 f 2.4 
readings taken pre-procedure with supplemental 
oxygen (B) to those after intravenous midazolam (C) 
there was a significant fall in both systolic and 
diastolic blood pressure and oxygen saturation and 
rise in pulse (P<O.OOl) for all comparisons using 
paired t-tests). 
Comparing pre-procedure with supplemental oxy- 
gen readings (B) to those after passing the broncho- 
scope through the larynx (D) there was a significant 
increase in systolic and diastolic blood pressure and 
pulse (P<O.OS, ~0.01, and <O.OOl respectively). 
There was also a significant fall in oxygen saturation 
(P<O.OOl). 
However, only 18 of the 123 patients de-saturated 
below 90% at any stage during the procedure. Brief 
de-saturation of 85-90% occurred in 16 patients just 
after passing the bronchoscope through the larynx 
and was associated with coughing. In two patients 
there was prolonged desaturation below 90%. One 
was obese with SVC obstruction and in the other 
considerable bleeding occurred. In both the sedation 
was rapidly reversed with intravenous flumazenil. 
Flumazenil was given to another 13 patients. One 
was because of concern over bleeding (without 
desaturation) but the other 12 because there were 
insufficient nursing staff available to look after 
recovery patients. 
On average patients took about an hour to wake 
up and about 2.5 h till judged to be fit to go home. 
Patients given intravenous flumazenil were excluded 
from the analysis of time till fit to go home. Six 
patients were admitted after the bronchoscopy. Three 
for control of pre-existing symptoms, one had an 
episode of hypotension associated with atria1 fibrilla- 
tion about 1.5 h after extubation and the other two 
with concern about bleeding. 
The dose of lignocaine instilled through the bron- 
choscope ranged from 80 to 320 mg (mean 172 mg) in 
addition to the 100 mg of lignocaine gel into the 
nostrils. 
No patient had a significant arrhythmia during the 
procedure. 
Of the 50 patients out of the first 73 who returned 
the questionnaire, one rated the procedure very 
unpleasant, nine mildly unpleasant and 40 not 
unpleasant. All patients were prepared to have 
another bronchoscopy and none remembered any- 
thing about the procedure after the midazolam injec- 
tion. Of the 50 who completed the questionnaire 
before going home one rated the procedure very 
unpleasant, five mildly unpleasant and 44 not 
unpleasant. All patients except one were prepared to 
have another bronchoscopy and none remembered 
anything about the procedure after the midazolam 
injection. 
Discussion 
Patients may find fibre optic bronchoscopy 
unpleasant. Our technique produces complete amne- 
sia for the procedure. No patient found it intolerable 
and only two very unpleasant. All patients except one 
were prepared to have another bronchoscopy. This 
compares with three recent studies. In one many 
patients had unpleasant symptoms during bronchos- 
copy and 25% would not agree to a repeat examina- 
tion. The authors concluded that doctors seriously 
underestimate the lack of acceptability and side 
effects experienced by patients undergoing broncho- 
scopy (1). In the second with intravenous fentanyl 
and droperidol 7% described the bronchoscopy as 
extremely unpleasant and 5% ‘worst thing ever 
happened to me’. Twenty-five percent would not 
agree to a repeat bronchoscopy (2). In the third using 
intravenous phenoperidine and droperidol patients 
found no difference between active and placebo 
treatment for comfort while those receiving active 
sedation were less willing to have the procedure 
repeated (5). 
There were statistically significant falls in oxygen 
saturation but prolonged de-saturation below 90% 
in only two patients. In both the saturation 
rapidly improved after reversing the sedation with 
flumazenil. 
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In terms of running a day case bronchoscopy 
service there are disadvantages in using this sedative 
technique. Firstly patients may take a long time to 
wake up. Secondly we felt that patients needed 
continuous nursing supervision after the procedure 
till they were awake as in a recovery room situation 
and used flumazenil if sufficient nurses were not 
available. Despite these disadvantages the nursing 
staff were very much in favour of the sedative tech- 
nique because of the total amnesia produced. 
We conclude that sedation with induction of 
anaesthesia doses of intravenous midazolam given by 
slow intravenous injection is a safe technique for fibre 
optic bronchoscopy with low morbidity and highly 
acceptable to patients. 
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